• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Risk for A-Fib Increased With Consumption of Sugar-Sweetened and Diet Beverages

Medically reviewed by Carmen Pope, BPharm. Last updated on March 13, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, March 13, 2024 -- Consumption of >2 L/week of sugar-sweetened beverages (SSB) or artificially sweetened beverages (ASB) is associated with an increased risk for atrial fibrillation (AF), according to a study published online March 5 in Circulation: Arrhythmia and Electrophysiology.

Ying Sun, M.D., from Shanghai Ninth People's Hospital, and colleagues examined the associations of consumption of SSB, ASB, and pure fruit juice (PJ) with AF risk and assessed whether these associations are modified by genetic susceptibility among 201,856 participants.

A total of 9,362 incident AF cases were documented during a median follow-up of 9.9 years. The researchers found that in the multivariable-adjusted model, individuals who consumed >2 L/week of SSB or ASB had an increased risk for AF compared with nonconsumers (hazard ratios, 1.10 and 1.20, respectively). There was a negative association for consumption of ≤1 L/week of PJ with AF risk (hazard ratio, 0.92). Participants at high genetic risk who consumed >2 L/week of ASB had the highest hazard ratio for AF (hazard ratio, 3.51), while the lowest risk was seen for those at low genetic risk who consumed ≤1 L/week of PJ (hazard ratio, 0.77).

"Our study's findings cannot definitively conclude that one beverage poses more health risk than another due to the complexity of our diets and because some people may drink more than one type of beverage," coauthor Ningjian Wang, M.D., Ph.D., also from Shanghai Ninth People's Hospital, said in a statement. "However, based on these findings, we recommend that people reduce or even avoid artificially sweetened and sugar-sweetened beverages whenever possible."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.